Meditation and Cognitive Function in Women With Breast Cancer
Feasibility Study of Meditation, Cognitive Function, and Quality of Life in Women With Breast Cancer
1 other identifier
interventional
47
1 country
1
Brief Summary
The goal of this behavioral research study is to learn if participating in a Tibetan meditation program helps to improve quality of life for women after chemotherapy and during recovery from breast cancer. Whether the meditation program helps to improve brain function and sleep quality will also be studied.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable breast-cancer
Started Oct 2007
Longer than P75 for not_applicable breast-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 24, 2007
CompletedFirst Submitted
Initial submission to the registry
November 7, 2007
CompletedFirst Posted
Study publicly available on registry
November 9, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 10, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 10, 2022
CompletedAugust 30, 2022
August 1, 2022
14.8 years
November 7, 2007
August 26, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Number of Eligible Women Approached Who Consented to be in Trial (Feasibility)
2 Years
Women's Reported Satisfaction with Tibetan Meditation intervention
2 Years
Study Arms (2)
Tibetan Meditation
OTHERNo Meditation
OTHERInterventions
12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
Eligibility Criteria
You may qualify if:
- Women with stage I - III breast cancer who have undergone chemotherapy (either neoadjuvant or adjuvant) 6 - 60 months prior to recruitment.
- Women who report cognitive impairment since starting chemotherapy as assessed by four questions from the FACT-Cog.
- Women must be 18 years or older.
- Women must be able to read, write and speak English.
- Women must be currently undergoing hormone therapy (e.g., Tamoxifen or AIs)
- Willing to come to MDACC for the meditation sessions and assessment sessions.
- Women must be within 2 hours driving distance of MDACC.
You may not qualify if:
- Women who have a documented diagnosis of a formal thought disorder (e.g., schizophrenia) will be excluded from the study.
- Women with metastatic disease to the brain or any past neurologic injury.
- Women with a Mini-Mental State Examination score of 23 or below.
- Women with recurrent cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lorenzo Cohen, PhD
M.D. Anderson Cancer Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 7, 2007
First Posted
November 9, 2007
Study Start
October 24, 2007
Primary Completion
August 10, 2022
Study Completion
August 10, 2022
Last Updated
August 30, 2022
Record last verified: 2022-08